All News

Trastuzumab deruxtecan shows promising efficacy in treating HER2-positive metastatic breast cancer with brain metastases, offering hope for challenging cases.

Sundar Jagannath, MD, MBBS, explains how linvoseltamab showed strong efficacy and tolerability in the LINKER-MM1 trial, making it an appealing option for older patients with relapsed or refractory multiple myeloma (MM).

CDC's ACIP recommends removing thimerosal from flu vaccines, igniting debate on vaccine safety and fueling antivaccine sentiments amid public health concerns.

In 2 clinical trials, oveporexton shows promise in treating narcolepsy type 1 (NT1), paving the way for potential FDA approval.

There were also no observed differences in retention rates or safety among patients with ankylosing spondylitis.

Sherie Loy-Helm, PharmD, has built a thriving independent pharmacy rooted in community, compassion, and outstanding service.

Particularly during summer months, counsel patients about sunscreen recommendations and drug-induced photosensitivity prevention strategies.

The decentralization of US health care, accelerated by virtual care adoption, shifting reimbursement models, and a growing demand for complex therapies, is elevating the role of specialty and infusion pharmacies as essential, tech-enabled partners in delivering coordinated, patient-centered care across outpatient and home-based settings.

High levels of remnant cholesterol were associated with increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) independent of low-density lipoprotein cholesterol (LDL-C).

Finerenone plays an emerging role in managing complex heart failure with preserved ejection fraction (HFpEF).

The approval represents a major advancement for patients with moderate-to-severe chronic hand eczema, as delgocitinib becomes the first treatment available for this population in the US.

Immense burden is laid upon patients with cancer who are infected with COVID-19, as they are at higher risk of experiencing cancer treatment disruptions and severe illness that necessitates hospitalization.

A Danish study confirms no link between aluminum in childhood vaccines and chronic diseases, reinforcing vaccine safety amid rising skepticism.

Adam James, PharmD, and Chris Altman, PharmD, explain how pharmacists can build trust and reduce vaccine hesitancy by clearly communicating thimerosal’s limited role in today’s immunizations and addressing patient concerns with empathy and education.

Eugene Przespolewski, PharmD, BCOP, DPLA, shares insights from his presentation at the 2025 OPC meeting in Austin, Texas.

A human-first support model helped boost adherence and outcomes, proving emotional connection is key to specialty medication success.

Even patients who are confident in their abilities often use incorrect technique

New research reveals uranium isotopes in urine as potential biomarkers for kidney damage, highlighting risks from contaminated drinking water in the US.

Pharmacists are pivotal in optimizing GLP-1 receptor agonist therapy.

Artificial intelligence (AI) is rapidly transforming oncology by enhancing clinical trial design, streamlining patient recruitment, improving precision medicine, and optimizing pharmacy operations, while raising important challenges around data ethics, bias, and integration into clinical workflows.

Carrie Harney, JD, of US Pharmacopeia (USP) discusses how proposed tariffs could impact generic drug supply chains, sterile injectable shortages, and pharmacy operations, underscoring the need for policy incentives and manufacturing diversification.

Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma.

UPMC Health Plan enhances COPD care through a multidisciplinary approach, leveraging telehealth, education, and pharmacist-led programs to optimize patient outcomes.

Results from the ZENITH trial show sotatercept's promise for pulmonary arterial hypertension treatment.

Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, explore how the removal of risk evaluation and management strategies (REMS) for chimeric antigen receptor (CAR) T-cell (CAR T) therapies can improve health equity, expand access in community settings, and elevate the pharmacist’s role in care coordination.

Omolola (Lola) A. Adeoye-Olatunde, PharmD, MS, discusses her passion for advancing community-engaged pharmacy research.

The plan first addresses monoclonal antibodies but could eventually be applied to all compounds seeking FDA approval.